Biobanks: Catalysts for Precision Medicine and Beyond – Exploring Applications, Ethical Frameworks, Technical Hurdles, and Economic Ramifications

Abstract

Biobanks, repositories of biological samples and associated data, have emerged as crucial infrastructure for biomedical research, playing a pivotal role in the advancement of precision medicine, drug discovery, and our understanding of disease mechanisms. This report delves into the multifaceted landscape of biobanking, moving beyond specific examples like salivary gland biobanks to explore the broader applications across various biomedical disciplines. We critically examine the ethical considerations inherent in biobanking practices, focusing on data privacy, informed consent, and the potential for discrimination. Furthermore, we address the technical challenges associated with maintaining high-quality biobanks, including sample storage, data management and harmonization, and the integration of ‘omics’ data. Finally, the report investigates the economic impact of biobanking on healthcare systems, considering the potential for cost savings through improved diagnostics, targeted therapies, and accelerated research and development. The report concludes by highlighting future directions for biobanking, emphasizing the need for international collaboration, standardized protocols, and a robust ethical and legal framework to maximize the benefits of biobanks while safeguarding individual rights and promoting public trust.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Biobanks represent a paradigm shift in biomedical research, transforming the traditional hypothesis-driven approach towards data-driven discovery. They serve as invaluable resources for researchers by providing access to well-characterized biological samples linked to comprehensive clinical and epidemiological data. This allows for the investigation of complex diseases, the identification of novel biomarkers, and the development of personalized therapies. Unlike traditional tissue banks that primarily focus on diagnostic or therapeutic purposes, biobanks are typically designed for research, often encompassing a wide range of biological materials, including blood, saliva, urine, tissue biopsies, and even microbial samples. Furthermore, the integration of ‘omics’ data (genomics, proteomics, metabolomics) with biobank samples offers unprecedented opportunities to unravel the molecular underpinnings of disease. The increasing accessibility of large, well-curated biobanks is fueling innovation in fields such as pharmacogenomics, personalized medicine, and regenerative medicine, ultimately leading to improved healthcare outcomes. It is worth noting that the term biobank is sometimes used to also refer to databases of health records, or even combinations of databases and sample repositories. For the purposes of this document, we will be considering biobanks to be physical sample repositories linked with clinical or research information.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Broad Applications of Biobanks in Medical Research

Biobanks have a vast range of applications across various medical disciplines. Some key areas include:

• Cancer Research: Biobanks are indispensable for cancer research, facilitating the identification of genetic and epigenetic alterations associated with tumor development and progression. They enable the study of tumor heterogeneity, the development of predictive biomarkers for treatment response, and the discovery of novel drug targets. Population-based biobanks, in particular, allow for the investigation of environmental and lifestyle factors that contribute to cancer risk. The UK Biobank, for instance, has been extensively used to explore the genetic basis of various cancers. Furthermore, cancer biobanks are crucial for the development of liquid biopsies, which offer a non-invasive approach for monitoring treatment response and detecting recurrence.
• Cardiovascular Disease Research: Biobanks are playing an increasingly important role in understanding the complex mechanisms underlying cardiovascular diseases (CVDs). They provide researchers with access to blood samples, tissue biopsies (e.g., from heart and vessels), and associated clinical data, enabling the identification of novel biomarkers for CVD risk, diagnosis, and prognosis. Furthermore, biobanks facilitate the study of genetic and environmental factors that contribute to CVD development and progression. For example, biobanks have been used to identify genetic variants associated with increased risk of coronary artery disease and heart failure. Moreover, biobanks are essential for the development of personalized therapies for CVDs, taking into account individual genetic profiles and disease subtypes.
• Infectious Disease Research: Biobanks are critical for studying infectious diseases, enabling the identification of novel pathogens, the characterization of host-pathogen interactions, and the development of diagnostic tools and vaccines. They provide researchers with access to samples from infected individuals, allowing for the study of viral, bacterial, and fungal infections. Biobanks are also essential for tracking the emergence and spread of drug-resistant pathogens, facilitating the development of new antimicrobial agents. During pandemics, such as the COVID-19 pandemic, biobanks played a vital role in rapidly characterizing the virus, developing diagnostic tests, and evaluating the efficacy of vaccines and therapeutics. The rapid response to the pandemic was facilitated by pre-existing biobanks that could be quickly repurposed for COVID-19 research.
• Neurological and Psychiatric Disorders: Biobanks are essential for unraveling the complex genetic and environmental factors that contribute to neurological and psychiatric disorders. These disorders often involve intricate interactions between multiple genes and environmental factors, making it challenging to identify specific disease mechanisms. Biobanks provide researchers with access to brain tissue, cerebrospinal fluid, and blood samples from patients with neurological and psychiatric disorders, enabling the identification of novel biomarkers and therapeutic targets. Furthermore, biobanks facilitate the study of disease progression and the development of personalized treatment strategies. The collection of post-mortem brain tissue is particularly valuable for studying neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
• Pharmacogenomics: Biobanks are increasingly used in pharmacogenomics research to identify genetic variants that influence drug response. This allows for the development of personalized drug therapies that are tailored to individual genetic profiles, maximizing efficacy and minimizing adverse effects. Biobanks provide researchers with access to DNA samples and clinical data from patients who have received specific medications, enabling the identification of genetic markers that predict drug response. This information can be used to guide drug selection and dosage, improving patient outcomes and reducing healthcare costs. For example, biobanks have been used to identify genetic variants that influence the metabolism of warfarin, a commonly used anticoagulant drug.
• Rare Disease Research: Biobanks are particularly valuable for studying rare diseases, which often affect small numbers of individuals. Due to the limited availability of samples from patients with rare diseases, biobanks provide a crucial resource for researchers to study these conditions. They facilitate the identification of disease-causing genes, the development of diagnostic tools, and the evaluation of potential therapies. International collaborations are essential for building large biobanks that include samples from patients with rare diseases, enabling researchers to study these conditions on a global scale.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Ethical Considerations Surrounding Biobanks

The ethical considerations surrounding biobanks are paramount, requiring careful consideration of data privacy, informed consent, and the potential for discrimination. A robust ethical framework is essential to ensure public trust and promote responsible use of biobank resources.

• Informed Consent: Obtaining informed consent from biobank participants is a fundamental ethical requirement. Participants must be fully informed about the purpose of the biobank, the types of samples and data that will be collected, how their samples and data will be used, and their rights to withdraw from the biobank at any time. The consent process should be transparent and easy to understand, and participants should have the opportunity to ask questions and receive clear answers. There are various models of consent, including broad consent, tiered consent, and dynamic consent. Broad consent allows researchers to use samples and data for a wide range of research purposes, while tiered consent allows participants to choose which types of research they are willing to participate in. Dynamic consent involves ongoing communication with participants, allowing them to update their consent preferences over time. The choice of consent model depends on the specific context of the biobank and the preferences of the participants. There is an ongoing debate about the validity of ‘broad consent’ with the argument that true consent requires a specific description of what the samples will be used for, but the practicalities of that level of specific consent for long term storage are virtually impossible to implement.
• Data Privacy and Confidentiality: Protecting the privacy and confidentiality of biobank participants is crucial. This requires implementing robust data security measures to prevent unauthorized access to sensitive information. Data should be anonymized or pseudonymized to protect the identity of participants. Anonymization involves removing all identifying information from the data, while pseudonymization involves replacing identifying information with a code or identifier. However, it is important to note that even anonymized data can potentially be re-identified, particularly with the increasing availability of genomic data. Therefore, it is essential to implement additional safeguards, such as data encryption and access controls, to protect data privacy. Regulations like the General Data Protection Regulation (GDPR) in Europe have significantly impacted biobanking practices, requiring stringent data protection measures and giving individuals greater control over their personal data. There is also the issue of sharing data across multiple research groups while still protecting the anonymity of the data. The ideal solution is to make the data available through a central online portal using a ‘bring the researchers to the data’ model, rather than sharing the data directly.
• Data Security: The increased risk of cyberattacks has also prompted the need for much greater levels of data security in biobanks.
• Genetic Discrimination: Biobanks raise concerns about the potential for genetic discrimination, where individuals may be discriminated against based on their genetic information. This could occur in various contexts, such as employment, insurance, or access to healthcare. To prevent genetic discrimination, it is essential to implement legal protections that prohibit the use of genetic information for discriminatory purposes. The Genetic Information Nondiscrimination Act (GINA) in the United States is an example of such legislation. However, GINA has limitations, as it does not cover life insurance, long-term care insurance, or disability insurance.
• Commercialization and Benefit Sharing: The commercialization of research findings derived from biobank samples raises ethical questions about benefit sharing. Should biobank participants receive a share of the profits generated from the commercialization of research findings? There are varying perspectives on this issue. Some argue that participants have a right to benefit from the commercialization of research findings, as their samples and data contributed to the discovery. Others argue that it is impractical to track down individual participants and distribute profits, and that the benefits should be shared with the broader community through reinvestment in research or healthcare. A common approach is to ensure that any commercial benefits are used to support further research and improve healthcare for the population from which the samples were obtained. However, transparency and accountability are essential to ensure that benefits are shared fairly and equitably. This also includes issues around intellectual property rights. It must be clearly documented at the beginning of the project what ownership rights the participant has, and how that right impacts on commercialisation of any derived products.
• Secondary Use of Data: The secondary use of biobank data for research purposes beyond the original intent raises ethical considerations about the scope of consent. While broad consent may allow for secondary use of data, it is important to ensure that such use is ethically justifiable and aligns with the values and interests of the participants. Researchers should seek ethical review and approval before using biobank data for secondary research purposes, and they should be transparent about how the data will be used. In some cases, it may be necessary to re-contact participants to obtain their consent for specific secondary uses of data. The European GDPR regulations attempt to ensure a balance between research use of data and the privacy needs of individuals.
• Privacy of Family Members: The use of genetic data derived from biobanks can potentially reveal information about family members who have not consented to participate in research. This raises ethical concerns about the privacy of family members and the potential for genetic discrimination. Researchers should take steps to protect the privacy of family members by anonymizing genetic data and limiting the disclosure of information that could identify them. Furthermore, researchers should provide genetic counseling to participants about the potential implications of genetic research for their family members.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Technical Challenges of Maintaining Biobanks

Maintaining high-quality biobanks presents several technical challenges, including sample storage, data management and harmonization, and the integration of ‘omics’ data. Overcoming these challenges is crucial for ensuring the reliability and reproducibility of research findings.

• Sample Storage: Proper sample storage is essential for maintaining the integrity of biological samples over long periods of time. Different types of samples require different storage conditions to prevent degradation. For example, DNA and RNA samples are typically stored at -80°C or in liquid nitrogen to prevent degradation by enzymes. Tissue samples may be stored in formalin-fixed paraffin-embedded (FFPE) blocks or cryopreserved in liquid nitrogen. The storage temperature, humidity, and storage container can all affect the quality of the samples. It is important to use standardized protocols for sample collection, processing, and storage to minimize variability and ensure consistency across samples. Furthermore, it is essential to monitor sample quality regularly and to implement quality control measures to detect and address any degradation that may occur. Automated storage systems can help to improve sample management and reduce the risk of human error. Remote monitoring of temperature and humidity can also reduce potential loss due to system failure.
• Data Management and Harmonization: Biobanks generate large amounts of data, including clinical data, demographic data, and ‘omics’ data. Managing and harmonizing these data is a significant challenge. Data must be stored in a secure and accessible database, and it must be linked to the corresponding biological samples. Data harmonization involves standardizing data formats and terminologies to ensure that data from different sources can be integrated and analyzed. This requires the use of common data elements (CDEs) and standardized ontologies. Data quality control is also essential to ensure the accuracy and reliability of the data. The development of interoperable data platforms is crucial for facilitating data sharing and collaboration among researchers. FAIR principles (Findable, Accessible, Interoperable, and Reusable) are becoming increasingly important for data management in biobanks. Some biobanks are starting to use blockchain technology to secure the integrity and auditability of their data.
• Integration of ‘Omics’ Data: The integration of ‘omics’ data (genomics, proteomics, metabolomics) with biobank samples offers unprecedented opportunities to unravel the molecular underpinnings of disease. However, integrating these data presents several technical challenges. ‘Omics’ data are typically high-dimensional and complex, requiring specialized analytical tools and expertise. Furthermore, ‘omics’ data must be linked to clinical data and other relevant information to provide a comprehensive understanding of the disease. Data normalization and batch effect correction are essential to minimize technical variability and ensure the accuracy of the results. The development of integrated data platforms that can handle ‘omics’ data and clinical data is crucial for facilitating translational research. The use of artificial intelligence and machine learning techniques can help to analyze complex ‘omics’ data and identify novel biomarkers and therapeutic targets. The amount of ‘omics’ data is also becoming extremely large, so the computational resources to analyse the data have become a practical limitation for some research projects.
• Sample Tracking and Chain of Custody: Maintaining a robust sample tracking system is essential for ensuring the integrity of biobank samples and data. This involves tracking the location of samples at all stages of the biobanking process, from collection to storage to analysis. A chain of custody system ensures that the samples are handled properly and that their integrity is maintained. Barcoding and RFID technology can be used to automate sample tracking and reduce the risk of human error. Electronic laboratory notebooks (ELNs) can also be used to document all procedures performed on the samples. Regular audits of the sample tracking system are necessary to identify and correct any errors or deficiencies.
• Automation and Robotics: Automation and robotics can play an important role in improving the efficiency and throughput of biobanking operations. Automated systems can be used for sample processing, storage, and retrieval. Robotics can be used to automate repetitive tasks, such as aliquoting and pipetting. Automation can reduce the risk of human error and improve the consistency of results. However, the implementation of automation requires significant investment in equipment and infrastructure. Furthermore, it is important to validate the performance of automated systems and to ensure that they are properly maintained.
• Sustainability: The ongoing funding and viability of biobanks is an ongoing issue. It is difficult to obtain funding for the long-term maintenance of the biobank, and more often funding is awarded to ‘use’ the resources in the biobank, rather than to actually maintain the samples. A viable long-term solution to this funding issue is still required.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Economic Impact of Biobanking on Healthcare

The economic impact of biobanking on healthcare is significant, with the potential for cost savings through improved diagnostics, targeted therapies, and accelerated research and development. The initial investment in establishing and maintaining biobanks can be substantial, but the long-term benefits can outweigh the costs.

• Improved Diagnostics: Biobanks facilitate the development of improved diagnostic tests that can detect diseases earlier and more accurately. This can lead to earlier treatment and improved patient outcomes. For example, biobanks have been used to identify novel biomarkers for cancer detection, allowing for the development of non-invasive blood tests that can detect cancer at an early stage. Early detection of disease can reduce the need for more expensive and invasive treatments later on, resulting in cost savings.
• Targeted Therapies: Biobanks enable the development of targeted therapies that are tailored to individual genetic profiles and disease subtypes. This can improve treatment efficacy and reduce the risk of adverse effects. For example, biobanks have been used to identify genetic variants that predict drug response, allowing clinicians to select the most effective drug for each patient. Targeted therapies can be more expensive than traditional therapies, but they can also be more effective, leading to improved patient outcomes and reduced healthcare costs in the long run.
• Accelerated Research and Development: Biobanks accelerate research and development by providing researchers with access to well-characterized biological samples and associated data. This can speed up the discovery of novel biomarkers, therapeutic targets, and diagnostic tools. The pharmaceutical industry relies heavily on biobanks for drug discovery and development. The availability of high-quality biobank samples can reduce the time and cost of drug development, leading to faster access to new treatments for patients.
• Reduced Healthcare Costs: By improving diagnostics, developing targeted therapies, and accelerating research and development, biobanks can contribute to reduced healthcare costs. Early detection of disease can reduce the need for more expensive treatments later on. Targeted therapies can improve treatment efficacy and reduce the risk of adverse effects, leading to fewer hospitalizations and doctor visits. Accelerated research and development can lead to faster access to new treatments and diagnostic tools, improving patient outcomes and reducing healthcare costs.
• Job Creation: Biobanking also creates jobs in the healthcare and research sectors. Biobanks require skilled personnel to manage and maintain the samples and data, as well as researchers to analyze the data and develop new diagnostic tools and therapies. The growth of the biobanking industry can contribute to economic growth and job creation.
• Return on Investment: Studies have shown that biobanks can provide a significant return on investment. A study by the RAND Corporation found that the UK Biobank could generate £2.4 billion in economic benefits over a 25-year period. These benefits include improved health outcomes, reduced healthcare costs, and increased economic productivity. However, it is important to note that the economic benefits of biobanking are difficult to quantify and may vary depending on the specific context.
• Public-Private Partnerships: Public-private partnerships can play an important role in funding and supporting biobanking initiatives. Governments, academic institutions, and private companies can collaborate to establish and maintain biobanks. Private companies can provide funding and expertise in areas such as data management and ‘omics’ analysis. Public-private partnerships can help to ensure the sustainability of biobanks and to maximize their impact on healthcare.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Future Directions

The future of biobanking is bright, with several promising directions for future development. These include the integration of new technologies, the development of standardized protocols, the expansion of international collaborations, and the establishment of a robust ethical and legal framework.

• Integration of New Technologies: New technologies, such as artificial intelligence, machine learning, and blockchain, are transforming the field of biobanking. Artificial intelligence and machine learning can be used to analyze complex ‘omics’ data and identify novel biomarkers and therapeutic targets. Blockchain technology can be used to secure the integrity and auditability of biobank data. Nanotechnology can be used to develop new methods for sample storage and analysis. The integration of these new technologies will enhance the capabilities of biobanks and accelerate research and development.
• Development of Standardized Protocols: The development of standardized protocols for sample collection, processing, storage, and analysis is crucial for ensuring the reliability and reproducibility of research findings. Standardized protocols minimize variability and ensure consistency across samples. International organizations, such as the International Society for Biological and Environmental Repositories (ISBER), are working to develop and promote standardized protocols for biobanking. The use of standardized protocols will improve the quality and comparability of data from different biobanks, facilitating collaboration and accelerating research.
• Expansion of International Collaborations: International collaborations are essential for building large biobanks that include samples from diverse populations. This will allow researchers to study diseases that affect different populations and to identify genetic and environmental factors that contribute to disease risk. International collaborations also facilitate the sharing of data and expertise, accelerating research and development. International organizations, such as the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-ERIC), are working to promote international collaborations in biobanking.
• Establishment of a Robust Ethical and Legal Framework: A robust ethical and legal framework is essential to ensure public trust and promote responsible use of biobank resources. This framework should address issues such as informed consent, data privacy, genetic discrimination, and benefit sharing. It should also provide clear guidelines for the secondary use of data and the commercialization of research findings. International organizations, such as the World Health Organization (WHO), are working to develop ethical guidelines for biobanking.
• Focus on Patient Engagement: Actively engaging patients in the biobanking process is becoming increasingly important. This includes involving patients in the design of biobank studies, providing them with feedback on research findings, and ensuring that their voices are heard. Patient engagement can help to build trust in biobanks and to ensure that research is relevant to their needs.
• Data Harmonization and Interoperability: Improving data harmonization and interoperability across biobanks remains a critical challenge. This requires the development of common data models and terminologies, as well as the implementation of data sharing platforms. The use of FAIR principles (Findable, Accessible, Interoperable, and Reusable) is essential for promoting data harmonization and interoperability. Standardisation of annotation practices is also important. For example using ontologies to describe the samples in a standardised way.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Conclusion

Biobanks are a critical infrastructure for biomedical research, playing a pivotal role in the advancement of precision medicine, drug discovery, and our understanding of disease mechanisms. They offer a vast range of applications across various medical disciplines, from cancer research to infectious disease research. However, maintaining high-quality biobanks presents several ethical and technical challenges. Ethical considerations surrounding data privacy, informed consent, and the potential for discrimination must be carefully addressed. Technical challenges related to sample storage, data management, and the integration of ‘omics’ data must be overcome. The economic impact of biobanking on healthcare is significant, with the potential for cost savings through improved diagnostics, targeted therapies, and accelerated research and development. The future of biobanking is bright, with several promising directions for future development, including the integration of new technologies, the development of standardized protocols, the expansion of international collaborations, and the establishment of a robust ethical and legal framework. By addressing the ethical and technical challenges and embracing new technologies and collaborations, biobanks can continue to play a vital role in improving human health and advancing biomedical knowledge.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

• Cambon-Thomsen, A., Thorisson, G. A., Mabile, L., & Rial-Sebbag, E. (2011). The role of biobanks in supporting future health research. Journal of Internal Medicine, 270(4), 322-334.
• Caulfield, T., & Kaye, J. (2008). Biobanks, research, and the public: trust, governance, and ethical issues. Clinical Genetics, 73(3), 203-211.
• Hansson, M. G., Dillner, J., Bartram, C. R., Carlson, J., Helgesson, G., & Hoeyer, K. (2006). An ethical framework for biobanking research. European Journal of Cancer, 42(11), 1632-1637.
• Hewitt, R. E. (2011). Biobanking: the foundation for personalized medicine. Current Opinion in Oncology, 23(1), 112-119.
• Khoury, M. J., Gwinn, M., Burke, W., Dotson, W. D., & Moonesinghe, R. (2007). The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of genomics into health care?. Genetics in Medicine, 9(10), 665-674.
• OECD. (2009). Biological Resource Centres: Underpinning the Future of Life Sciences and Biotechnology. OECD Publishing.
• EBI -EMBL: https://www.ebi.ac.uk/
• BBMRI-ERIC: https://www.bbmri-eric.eu/
• FAIR Principles: https://www.go-fair.org/fair-principles/
• UK Biobank: https://www.ukbiobank.ac.uk/
• CODATA: https://codata.org/
• Genetic Information Nondiscrimination Act (GINA): https://www.eeoc.gov/statutes/genetic-information-nondiscrimination-act-2008
• General Data Protection Regulation (GDPR) (https://gdpr-info.eu/)
• International Society for Biological and Environmental Repositories (ISBER): https://www.isber.org/